Recently, TGFβ has emerged as a promising treatment target in combination with PD-1/PD-L1 blockade in multiple tumor models; TGFβ signaling in fibroblasts prevents cytotoxic T lymphocyte (CTL) infiltration into tumors, while PD-L1 expression in the tumors inhibits effector T cell function14–17. The gene discussed is PDCD1; the disease is neoplasm.